Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
Rocket Pharmaceuticals, Inc. (RCKT) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting.
- Quorum: 91,366,461 shares represented, or approximately 85.56% of outstanding common stock.
- Director elections: All ten nominees were elected. “For” votes ranged from 55.35 M to 78.60 M, with David P. Southwell receiving the highest opposition (23.79 M withheld).
- Auditor ratification: EisnerAmper LLP approved with 90.70 M For, 0.14 M Against, 0.53 M Abstain.
- Say-on-Pay: Executive compensation passed on an advisory basis (77.19 M For, 1.44 M Against, 0.52 M Abstain).
The vote results indicate broad shareholder support for the board, management and governance practices; no other material events were disclosed.